Global Anti Malarial Drug Market
Global Anti Malarial Drug Market

Anti Malarial Drug Comprehensive Study by Type (Chloroquine Phosphate, Artemisinin, Others), End Users (Hospitals, Clinics, Households), Drug Classes (Quinoline, Antifolates, Artemisinin, Antimicrobials), Distribution Channels (Online {Company Website, E-Commerce Website}, Offline {Pharma Stores, Local Medical Stores}) Players and Region - Global Market Outlook to 2026

Anti Malarial Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Oct 2021 Edition 210 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Anti Malarial Drug Market Scope?
Antimalarial Drugs are used to treat and prevent malaria disease. The majority of antimalarial medications are directed at the erythrocytic stage of malaria infection, which is the stage of infection that results in symptoms. For most antimalarial medicines, the level of pre-erythrocytic (hepatic stage) action is unknown. Malaria induced by all malaria species requires treatment of the acute blood stage infection. Furthermore, for infections caused by Plasmodium ovale or Plasmodium vivax, terminal prophylaxis with a hypnozoite-killing medication is essential (which can remain dormant in the liver for months and, occasionally, years after the initial infection).

The Anti Malarial Drug market study is being classified by Type (Chloroquine Phosphate, Artemisinin and Others) and major geographies with country level break-up.

The demand for Nucleic Acid Electrophoresis is increasing with each passing day. Businesses in this area face fierce rivalry on a global basis from market leaders who control a large share of the market. The Leading Players are engaged in organic and non-organic strategic global expansion to maintain their Market Position. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Anti Malarial Drug market throughout the predicted period.

Cadila Healthcare (India), Alvizia Healthcare Pvt. Ltd. (India), Novartis (Switzerland), Pfizer (United States), Roche Holding AG (Switzerland), Sun Pharmaceuticals (India), GlaxoSmithKline (United Kingdom), Glenmark Pharmaceuticals (India), Merck & Co (United States) and Cipla (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Wallace Pharmaceuticals (India), Bliss GVS Pharma (India) and Ipca Laboratories Ltd (India).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Anti Malarial Drug market by Type, Application and Region.

On the basis of geography, the market of Anti Malarial Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On September 29 Novartis released a statement announcing the success of its New non-artemisinin combination in a Phase 2b study with Medicines for Malaria Venture (MMV). The researchers combined ganaplacide, a novel drug with a completely different mode of action, with a new lumefantrine formulation optimized for once-daily dosing. This combination has the potential to not only cure malaria infection, including artemisinin-resistant forms but also to prevent the parasite from spreading. Ganaplacide fulfilled the primary study goal in children under the age of 12 years old in Phase 2b research.


Influencing Market Trend
  • Rapid Development of Plant-Based Antimalarial Drugs

Market Drivers
  • The SRising Incidence of Malaria Cases and Deaths in African, Asia, Eastern Mediterranean and Western Pacificurge in Disease by Malaria across the Globe
  • Increased Demand of Antimalarial Drug by Travelers

Opportunities
  • Rising Incidence of Malaria Cases and Deaths in African, Asia, Eastern Mediterranean and Western Pacific

Restraints
  • Side-Effects of Antimalarial Drugs Such as Dizziness, Headache, and Sleep Disturbances

Challenges
  • The Emergence of Parasite Bacteria


Key Target Audience
Venture and Capitalist, New Entrants/Investors, Analysts and Strategic Business Partners, Hospitals, Clinics and End-Use Industries

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Anti Malarial Drug market expands?
The Global Anti Malarial Drug market is expected to see a growth of % during projected year 2020 to 2026.

2. Who are the prominent players of the Global Anti Malarial Drug market?
The prominent players of Global Anti Malarial Drug market are Cadila Healthcare (India), Alvizia Healthcare Pvt. Ltd. (India), Novartis (Switzerland), Pfizer (United States), Roche Holding AG (Switzerland), Sun Pharmaceuticals (India), GlaxoSmithKline (United Kingdom), Glenmark Pharmaceuticals (India), Merck & Co (United States) and Cipla (India), to name a few.

3. What are the top priorities to focus for Anti Malarial Drug marketís growth?
In this highly competitive & fast evolving Anti Malarial Drug industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Chloroquine Phosphate
  • Artemisinin
  • Others
By End Users
  • Hospitals
  • Clinics
  • Households

By Drug Classes
  • Quinoline
  • Antifolates
  • Artemisinin
  • Antimicrobials

By Distribution Channels
  • Online {Company Website, E-Commerce Website}
  • Offline {Pharma Stores, Local Medical Stores}

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The SRising Incidence of Malaria Cases and Deaths in African, Asia, Eastern Mediterranean and Western Pacificurge in Disease by Malaria across the Globe
      • 3.2.2. Increased Demand of Antimalarial Drug by Travelers
    • 3.3. Market Challenges
      • 3.3.1. The Emergence of Parasite Bacteria
    • 3.4. Market Trends
      • 3.4.1. Rapid Development of Plant-Based Antimalarial Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti Malarial Drug, by Type, End Users, Drug Classes, Distribution Channels and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Anti Malarial Drug (Value)
      • 5.2.1. Global Anti Malarial Drug by: Type (Value)
        • 5.2.1.1. Chloroquine Phosphate
        • 5.2.1.2. Artemisinin
        • 5.2.1.3. Others
      • 5.2.2. Global Anti Malarial Drug by: End Users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Households
      • 5.2.3. Global Anti Malarial Drug by: Drug Classes (Value)
        • 5.2.3.1. Quinoline
        • 5.2.3.2. Antifolates
        • 5.2.3.3. Artemisinin
        • 5.2.3.4. Antimicrobials
      • 5.2.4. Global Anti Malarial Drug by: Distribution Channels (Value)
        • 5.2.4.1. Online {Company Website, E-Commerce Website}
        • 5.2.4.2. Offline {Pharma Stores, Local Medical Stores}
      • 5.2.5. Global Anti Malarial Drug Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Anti Malarial Drug (Price)
      • 5.3.1. Global Anti Malarial Drug by: Type (Price)
  • 6. Anti Malarial Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cadila Healthcare (India)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alvizia Healthcare Pvt. Ltd. (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Holding AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sun Pharmaceuticals (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Glenmark Pharmaceuticals (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck & Co (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Cipla (India)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Anti Malarial Drug Sale, by Type, End Users, Drug Classes, Distribution Channels and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Anti Malarial Drug (Value)
      • 7.2.1. Global Anti Malarial Drug by: Type (Value)
        • 7.2.1.1. Chloroquine Phosphate
        • 7.2.1.2. Artemisinin
        • 7.2.1.3. Others
      • 7.2.2. Global Anti Malarial Drug by: End Users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Households
      • 7.2.3. Global Anti Malarial Drug by: Drug Classes (Value)
        • 7.2.3.1. Quinoline
        • 7.2.3.2. Antifolates
        • 7.2.3.3. Artemisinin
        • 7.2.3.4. Antimicrobials
      • 7.2.4. Global Anti Malarial Drug by: Distribution Channels (Value)
        • 7.2.4.1. Online {Company Website, E-Commerce Website}
        • 7.2.4.2. Offline {Pharma Stores, Local Medical Stores}
      • 7.2.5. Global Anti Malarial Drug Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Anti Malarial Drug (Price)
      • 7.3.1. Global Anti Malarial Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti Malarial Drug: by Type(USD Million)
  • Table 2. Anti Malarial Drug Chloroquine Phosphate , by Region USD Million (2015-2020)
  • Table 3. Anti Malarial Drug Artemisinin , by Region USD Million (2015-2020)
  • Table 4. Anti Malarial Drug Others , by Region USD Million (2015-2020)
  • Table 5. Anti Malarial Drug: by End Users(USD Million)
  • Table 6. Anti Malarial Drug Hospitals , by Region USD Million (2015-2020)
  • Table 7. Anti Malarial Drug Clinics , by Region USD Million (2015-2020)
  • Table 8. Anti Malarial Drug Households , by Region USD Million (2015-2020)
  • Table 9. Anti Malarial Drug: by Drug Classes(USD Million)
  • Table 10. Anti Malarial Drug Quinoline , by Region USD Million (2015-2020)
  • Table 11. Anti Malarial Drug Antifolates , by Region USD Million (2015-2020)
  • Table 12. Anti Malarial Drug Artemisinin , by Region USD Million (2015-2020)
  • Table 13. Anti Malarial Drug Antimicrobials , by Region USD Million (2015-2020)
  • Table 14. Anti Malarial Drug: by Distribution Channels(USD Million)
  • Table 15. Anti Malarial Drug Online {Company Website, E-Commerce Website} , by Region USD Million (2015-2020)
  • Table 16. Anti Malarial Drug Offline {Pharma Stores, Local Medical Stores} , by Region USD Million (2015-2020)
  • Table 17. South America Anti Malarial Drug, by Country USD Million (2015-2020)
  • Table 18. South America Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 19. South America Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 20. South America Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 21. South America Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 22. Brazil Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 23. Brazil Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 24. Brazil Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 25. Brazil Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 26. Argentina Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 27. Argentina Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 28. Argentina Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 29. Argentina Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 30. Rest of South America Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 31. Rest of South America Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 32. Rest of South America Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 33. Rest of South America Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 34. Asia Pacific Anti Malarial Drug, by Country USD Million (2015-2020)
  • Table 35. Asia Pacific Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 36. Asia Pacific Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 37. Asia Pacific Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 38. Asia Pacific Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 39. China Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 40. China Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 41. China Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 42. China Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 43. Japan Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 44. Japan Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 45. Japan Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 46. Japan Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 47. India Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 48. India Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 49. India Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 50. India Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 51. South Korea Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 52. South Korea Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 53. South Korea Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 54. South Korea Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 55. Taiwan Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 56. Taiwan Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 57. Taiwan Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 58. Taiwan Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 59. Australia Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 60. Australia Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 61. Australia Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 62. Australia Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 63. Rest of Asia-Pacific Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 64. Rest of Asia-Pacific Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 65. Rest of Asia-Pacific Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 67. Europe Anti Malarial Drug, by Country USD Million (2015-2020)
  • Table 68. Europe Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 69. Europe Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 70. Europe Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 71. Europe Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 72. Germany Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 73. Germany Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 74. Germany Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 75. Germany Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 76. France Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 77. France Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 78. France Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 79. France Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 80. Italy Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 81. Italy Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 82. Italy Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 83. Italy Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 84. United Kingdom Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 85. United Kingdom Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 86. United Kingdom Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 87. United Kingdom Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 88. Netherlands Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 89. Netherlands Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 90. Netherlands Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 91. Netherlands Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 92. Rest of Europe Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 93. Rest of Europe Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 94. Rest of Europe Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 95. Rest of Europe Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 96. MEA Anti Malarial Drug, by Country USD Million (2015-2020)
  • Table 97. MEA Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 98. MEA Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 99. MEA Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 100. MEA Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 101. Middle East Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 102. Middle East Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 103. Middle East Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 104. Middle East Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 105. Africa Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 106. Africa Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 107. Africa Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 108. Africa Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 109. North America Anti Malarial Drug, by Country USD Million (2015-2020)
  • Table 110. North America Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 111. North America Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 112. North America Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 113. North America Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 114. United States Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 115. United States Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 116. United States Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 117. United States Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 118. Canada Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 119. Canada Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 120. Canada Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 121. Canada Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 122. Mexico Anti Malarial Drug, by Type USD Million (2015-2020)
  • Table 123. Mexico Anti Malarial Drug, by End Users USD Million (2015-2020)
  • Table 124. Mexico Anti Malarial Drug, by Drug Classes USD Million (2015-2020)
  • Table 125. Mexico Anti Malarial Drug, by Distribution Channels USD Million (2015-2020)
  • Table 126. Anti Malarial Drug: by Type(USD/Units)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Anti Malarial Drug: by Type(USD Million)
  • Table 138. Anti Malarial Drug Chloroquine Phosphate , by Region USD Million (2021-2026)
  • Table 139. Anti Malarial Drug Artemisinin , by Region USD Million (2021-2026)
  • Table 140. Anti Malarial Drug Others , by Region USD Million (2021-2026)
  • Table 141. Anti Malarial Drug: by End Users(USD Million)
  • Table 142. Anti Malarial Drug Hospitals , by Region USD Million (2021-2026)
  • Table 143. Anti Malarial Drug Clinics , by Region USD Million (2021-2026)
  • Table 144. Anti Malarial Drug Households , by Region USD Million (2021-2026)
  • Table 145. Anti Malarial Drug: by Drug Classes(USD Million)
  • Table 146. Anti Malarial Drug Quinoline , by Region USD Million (2021-2026)
  • Table 147. Anti Malarial Drug Antifolates , by Region USD Million (2021-2026)
  • Table 148. Anti Malarial Drug Artemisinin , by Region USD Million (2021-2026)
  • Table 149. Anti Malarial Drug Antimicrobials , by Region USD Million (2021-2026)
  • Table 150. Anti Malarial Drug: by Distribution Channels(USD Million)
  • Table 151. Anti Malarial Drug Online {Company Website, E-Commerce Website} , by Region USD Million (2021-2026)
  • Table 152. Anti Malarial Drug Offline {Pharma Stores, Local Medical Stores} , by Region USD Million (2021-2026)
  • Table 153. South America Anti Malarial Drug, by Country USD Million (2021-2026)
  • Table 154. South America Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 155. South America Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 156. South America Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 157. South America Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 158. Brazil Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 159. Brazil Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 160. Brazil Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 161. Brazil Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 162. Argentina Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 163. Argentina Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 164. Argentina Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 165. Argentina Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 166. Rest of South America Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 167. Rest of South America Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 168. Rest of South America Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 169. Rest of South America Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 170. Asia Pacific Anti Malarial Drug, by Country USD Million (2021-2026)
  • Table 171. Asia Pacific Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 172. Asia Pacific Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 173. Asia Pacific Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 174. Asia Pacific Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 175. China Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 176. China Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 177. China Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 178. China Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 179. Japan Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 180. Japan Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 181. Japan Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 182. Japan Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 183. India Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 184. India Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 185. India Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 186. India Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 187. South Korea Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 188. South Korea Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 189. South Korea Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 190. South Korea Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 191. Taiwan Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 192. Taiwan Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 193. Taiwan Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 194. Taiwan Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 195. Australia Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 196. Australia Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 197. Australia Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 198. Australia Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 199. Rest of Asia-Pacific Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 200. Rest of Asia-Pacific Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 201. Rest of Asia-Pacific Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 202. Rest of Asia-Pacific Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 203. Europe Anti Malarial Drug, by Country USD Million (2021-2026)
  • Table 204. Europe Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 205. Europe Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 206. Europe Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 207. Europe Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 208. Germany Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 209. Germany Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 210. Germany Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 211. Germany Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 212. France Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 213. France Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 214. France Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 215. France Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 216. Italy Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 217. Italy Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 218. Italy Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 219. Italy Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 220. United Kingdom Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 221. United Kingdom Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 222. United Kingdom Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 223. United Kingdom Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 224. Netherlands Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 225. Netherlands Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 226. Netherlands Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 227. Netherlands Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 228. Rest of Europe Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 229. Rest of Europe Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 230. Rest of Europe Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 231. Rest of Europe Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 232. MEA Anti Malarial Drug, by Country USD Million (2021-2026)
  • Table 233. MEA Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 234. MEA Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 235. MEA Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 236. MEA Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 237. Middle East Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 238. Middle East Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 239. Middle East Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 240. Middle East Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 241. Africa Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 242. Africa Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 243. Africa Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 244. Africa Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 245. North America Anti Malarial Drug, by Country USD Million (2021-2026)
  • Table 246. North America Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 247. North America Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 248. North America Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 249. North America Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 250. United States Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 251. United States Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 252. United States Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 253. United States Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 254. Canada Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 255. Canada Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 256. Canada Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 257. Canada Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 258. Mexico Anti Malarial Drug, by Type USD Million (2021-2026)
  • Table 259. Mexico Anti Malarial Drug, by End Users USD Million (2021-2026)
  • Table 260. Mexico Anti Malarial Drug, by Drug Classes USD Million (2021-2026)
  • Table 261. Mexico Anti Malarial Drug, by Distribution Channels USD Million (2021-2026)
  • Table 262. Anti Malarial Drug: by Type(USD/Units)
  • Table 263. Research Programs/Design for This Report
  • Table 264. Key Data Information from Secondary Sources
  • Table 265. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti Malarial Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Anti Malarial Drug: by End Users USD Million (2015-2020)
  • Figure 6. Global Anti Malarial Drug: by Drug Classes USD Million (2015-2020)
  • Figure 7. Global Anti Malarial Drug: by Distribution Channels USD Million (2015-2020)
  • Figure 8. South America Anti Malarial Drug Share (%), by Country
  • Figure 9. Asia Pacific Anti Malarial Drug Share (%), by Country
  • Figure 10. Europe Anti Malarial Drug Share (%), by Country
  • Figure 11. MEA Anti Malarial Drug Share (%), by Country
  • Figure 12. North America Anti Malarial Drug Share (%), by Country
  • Figure 13. Global Anti Malarial Drug: by Type USD/Units (2015-2020)
  • Figure 14. Global Anti Malarial Drug share by Players 2020 (%)
  • Figure 15. Global Anti Malarial Drug share by Players (Top 3) 2020(%)
  • Figure 16. Global Anti Malarial Drug share by Players (Top 5) 2020(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Cadila Healthcare (India) Revenue, Net Income and Gross profit
  • Figure 19. Cadila Healthcare (India) Revenue: by Geography 2020
  • Figure 20. Alvizia Healthcare Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 21. Alvizia Healthcare Pvt. Ltd. (India) Revenue: by Geography 2020
  • Figure 22. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 23. Novartis (Switzerland) Revenue: by Geography 2020
  • Figure 24. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 25. Pfizer (United States) Revenue: by Geography 2020
  • Figure 26. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Roche Holding AG (Switzerland) Revenue: by Geography 2020
  • Figure 28. Sun Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 29. Sun Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 30. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 31. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 32. Glenmark Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 33. Glenmark Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 34. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 35. Merck & Co (United States) Revenue: by Geography 2020
  • Figure 36. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 37. Cipla (India) Revenue: by Geography 2020
  • Figure 38. Global Anti Malarial Drug: by Type USD Million (2021-2026)
  • Figure 39. Global Anti Malarial Drug: by End Users USD Million (2021-2026)
  • Figure 40. Global Anti Malarial Drug: by Drug Classes USD Million (2021-2026)
  • Figure 41. Global Anti Malarial Drug: by Distribution Channels USD Million (2021-2026)
  • Figure 42. South America Anti Malarial Drug Share (%), by Country
  • Figure 43. Asia Pacific Anti Malarial Drug Share (%), by Country
  • Figure 44. Europe Anti Malarial Drug Share (%), by Country
  • Figure 45. MEA Anti Malarial Drug Share (%), by Country
  • Figure 46. North America Anti Malarial Drug Share (%), by Country
  • Figure 47. Global Anti Malarial Drug: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Cadila Healthcare (India)
  • Alvizia Healthcare Pvt. Ltd. (India)
  • Novartis (Switzerland)
  • Pfizer (United States)
  • Roche Holding AG (Switzerland)
  • Sun Pharmaceuticals (India)
  • GlaxoSmithKline (United Kingdom)
  • Glenmark Pharmaceuticals (India)
  • Merck & Co (United States)
  • Cipla (India)
Additional players considered in the study are as follows:
Wallace Pharmaceuticals (India) , Bliss GVS Pharma (India) , Ipca Laboratories Ltd (India)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation